• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

CBER on Twitter

Follow CBER on Twitter

FDA's Center for Biologics Evaluation and Research (CBER) has added the social media site Twitter to its communication and outreach program. CBER's main goal for Twitter is to provide up-to-date information to consumers, health professionals, regulated industry and other interested stakeholders about CBER regulated products. Messages on Twitter will include product approvals, safety information, upcoming meetings, new and updated guidance documents, compliance actions and other information of interest.

FDA CBER Exit Disclaimer

Disclaimer

We are not able to respond to replies or direct messages. Please do not reply to tweets with any private, personal, or proprietary information. Send all questions or comments to the email addresses listed below, or call us at (800) 835-4709 or (301) 827-1800.

Consumers and Health Professionals: OCOD@fda.hhs.gov

Industry: Industry.Biologics@fda.hhs.gov

Messages, followers, and those we are following do not in any way imply endorsement of any product or organization.